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TGF- and phorbol esters inhibit mitogenesis utilizing parallel protein
kinase C-dependent pathways. Transforming growth factor (TGF)-f3
mediates matrix production in both mesangial and vascular smooth muscle
cells. Both TGF-J3 and phorbol-12-myristate-13-acetate (PMA) exert both
positive and negative effects on mitogenesis in these as well as other cell
types. Phorbol esters act through stimulation of protein kinase C (PKC)
and are among the most potent tumor promoters known. The present
study was conducted to determine if the growth inhibitory effect of TGF-13
parallels that of the phorbol esters and whether this effect of TGF-13 is
dependent on activation of PKC. We show that, in vascular smooth muscle
cells stimulated to divide by the addition of the serum component basic
fibroblast growth factor (bFGF), TGF-pl inhibits mitogenesis in a dose-
dependent manner, by a maximum of 79% when applied at a concentra-
tion of 1 ng/ml. Furthermore, the inhibitory effect on mitogenesis of either
TGF-131 or PMA, when added four hours after bFGF, are 71% and 84%,
respectively. Both TGF-/31 and PMA cause translocation of cellular PKC
with similar time courses, while neither PKC-a nor PKC-131I are increased
in quantity in response to TGF-pl. In addition, down-regulation of PKC
by 24 hours incubation with PMA abolishes TGF-13's inhibitory effect in
bFGF-stimulated cells. We conclude that (i) the signaling pathway utilized
by TGF-p resulting in inhibition of mitogenesis parallels that of PMA, and(ii) the inhibitory effect of TGF-(31 on bFGF-induced mitogenesis is
partially due to activation of PKC. These data suggest that TGF-13 may be
an endogenous activator of the growth-inhibitory pathway of PKC, and,
since cellular differentiated functions generally occur when the cells are
proliferation-inhibited, PKC may be a modulator of extracellular matrix
deposition.
Transforming growth factor (TGF)-f3, originally defined by its
ability to stimulate anchorage-independent growth of non-neo-
plastic cells [1], has since been shown to be a multifunctional
growth-regulating peptide. Indeed, since the historical description
of this protein in bovine kidney [2], it has been shown to be
neither transforming nor consistently growth-promoting: depend-
ing on the cell system and the conditions of culture, TGF-f3 can be
either stimulatory or inhibitory on a multitude of cell functions
[reviewed in 1]. In animal models, this growth factor has been
implicated in a variety of diseases characterized by excessive
fibrosis affecting multiple organ systems [3, 4]. In the renal and
cardiovascular systems, TGF-13 has been shown to play key roles
in the mediation of glomerular scarring [5], and, along with other
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growth factors, has been implicated in the pathophysiology of
hypertension and atherosclerotic disease [61, being released upon
platelet aggregation and after vascular smooth muscle (VSM) cell
injury [7]. While it has recently been shown that TGF-j3 signals
through a heterodimeric protein kinase receptor complex [8], the
mechanism of signaling by the TGF-13 receptor downstream of
heterodimer formation has not been elucidated. The purpose of
the growth inhibitory action of TGF-f3 is hypothesized as allowing
the cells to devote their energy to perform differentiated func-
tions, such as basement membrane formation and extracellular
matrix deposition [9].
Phorbol esters are potent tumor promoters which, although not
carcinogenic by themselves, dramatically increase the incidence of
tumors when applied to animals that have received a carcinogen
at a sub-threshold dose [10]. These compounds regulate a com-
plex array of intracellular processes and appear to cause their
principal effects by continuous activation of protein kinase C
(PKC), since abolition or inhibition of PKC, in most cases,
abrogates these effects. Furthermore, it has been suggested that
activation of PKC causes cells to traverse the G01G1 transition,
since diacylglycerol and phorbol ester can replace competence
factors in NIH 3T3 cells [10]. However, while phorbol esters
synergistically stimulate DNA synthesis when added to cells
together with many growth factors [11], several systems have been
described in which these substances cause inhibition of cell
proliferation [12—15] or stimulation of differentiation [16]. In a
similar manner to their growth stimulatosy effects, the inhibitory
actions of phorbol esters have also been shown to be due to PKC
stimulation, as this effect was mimicked by diacylglycerol [15] and
abolished after incubation with the PKC inhibitor sphingosine
[17].
Since phorbol esters and TGF-f3 both have analogous pleiotro-
pic effects on mitogenesis, we suspected that their signaling
cascades act on parallel pathways. Since we are examining an
inhibitory effect on mitogenesis, we used basic fibroblast growth
factor (bFGF), a growth factor present in normal serum, to
stimulate DNA synthesis. We now show that both TGF-f3 and
phorbol-12-myristate-13-acetate (PMA) inhibit bFGF-induced
mitogenesis in a similar manner and cause parallel translocation
of PKC. Furthermore, our data suggest that the inhibitory effect
of TGF-131 on bFGF-induced mitogenesis is due at least in part to
activation of PKC, since down-regulation of PKC attenuates the
growth-inhibitory effect of TGF-/3. These results are the first to
our knowledge to provide a link between a growth-inhibitory,
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fibrosis-mediating, matrix-expanding pathway and a tumor pro-
moter. The evolutionary rationale for relating these disparate
events is unclear. However, since many inhibitors and activators of
phorbol esters have been described, such a link with TGF-13 may
lead to avenues of therapeutic exploration.
Methods
Materials
Human recombinant bFGF and human platelet extracted
TGF-/31 were obtained from UBI (Lake Placid, NY, USA).
Affinity-purified rabbit polyclonal antibodies to PKC-a and PKC-
/311 and blocking peptide C-20 to PKC-a were obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Goat
anti-rabbit horseradish peroxidase-linked IgG was obtained from
BioRad (Richmond, CA, USA). [3H]thymidine, y[32P]ATP, and
reagents for the Enhanced Chemiluminescence (ECL) system
were obtained from Amersham (Arlington Heights, IL, USA).
The Pierce Colorimetric PKC Assay Kit was obtained from Pierce
(Rockford, IL, USA). All other reagents were from Sigma (St.
Louis, MO, USA).
Cell culture
Cultures of VSM cells from 200 g Sprague-Dawley rats were
obtained at passage 5 from Dr. Jerry Powell at the University of
California, Davis, and the cells were used between passages 5 to
10. The cells were maintained in minimal essential medium with
10% fetal bovine serum, 2% tiyptose phosphate broth, penicillin
(50 U/ml) and streptomycin (50 U/mi) in a humidified atmosphere
of 5% C02, 95% air at 37°C. Culture medium was changed every
other day until the cells were confluent. The cells were growth-
arrested by placing them in quiescence medium containing mini-
mal essential medium, 20 mm HEPES (pH 7.4), 5 g/ml trans-
ferrin, 0.5 mg/ml bovine serum albumin, penicillin (50 U/mi) and
streptomycin (50 U/mi). Quiescence medium was changed daily
for two days prior to each experiment. Ceiis were harvested with
5 ml trypsin and subcultured at a 1:10 dilution weekly.
DNA synthesis
Cultured VSM cells were harvested, plated onto 24-well plates,
and grown to confluence, The confluent monolayers were then
placed in quiescence medium for an additional three days. Cells
were then exposed to growth factors as indicated. After 18 hours,
cells were pulsed for five hours with 1 jiCi/ml [3H]thymidine. The
cells were then fixed with I ml of 15% trichloroacetic acid, and
trichioroacetic acid-insoluble radioactivity was measured in a
scintillation counter.
Western blots
VSM cells were grown to confluence on 6 cm culture dishes and
quiesced as above. TGF-pI (5 nglml) was added to the medium
for the indicated times. The monolayer of cells was washed twice
with ice-cold phosphate-buffered saline and lysed in place by the
addition of ice-cold RIPA buffer [1% NP4O, 0.5% sodium deoxy-
cholate, 0.1% SDS, 100 mg/mi phenylmethylsulfonyl fluoride
(freshly prepared), 1 mg/mI aprotinin, 1 ifiM sodium orthovana-
date (1 ml/6 cm dish)]. After 30 minutes of incubation at 4°C, the
lysate was scraped off with a rubber policeman and centrifuged at
14,000 rpm at 4°C for 30 minutes. The supernatant was saved and
the protein concentration determined spectrophotometrically at
A595 with the BioRad protein concentration reagent. Aliquots
containing identical amounts of protein for each lysate were
heated in a boiling water bath for five minutes, loaded onto a 7.5%
polyacrylamide gel with 4% stacking gel with appropriate molec-
ular weight standards, and electrophoresed at 25 mA for two to
four hours. Subsequently, the gel was electrophoreticaily trans-
ferred onto a nitrocellulose filter in transfer buffer (192 mM
glycine, 25 mivi Tris, 20% methanol, pH 8.3). The nitrocelluiose
filters were blocked for one hour with 10% nonfat dried milk in
TBS-T (200 mi Tris, 5 M NaCl, pH 7.5, 0.05% Tween 20), washed
in TBS-T, and incubated at room temperature for one hour in a
1:50 dilution of rabbit polyclonal anti-PKC-a or rabbit polycional
anti-PKC-/311. The filter was washed again in TBS-T and incu-
bated for one hour with a 1:1,000 dilution of goat anti-rabbit
horseradish peroxidase coupled IgG. The final washes were with
TBS-T. The ECL system was used for detection. ECL reagents
were mixed 1:1 and applied to the filter which was subsequently
exposed to film for from 15 seconds to 15 minutes and the film
processed. For peptide neutralization, the blocking peptide was
incubated with the first antibody in the same solution at a
concentration tenfold higher; the later steps were identical.
PKC assays
For preparation of cytosolic and membrane fractions, VSM
cells were grown to confluence on 6 cm culture dishes and
quiesced as above. Cells were stimulated by either PMA (100
ng/ml), TGF-131 (5 ng/ml), or angiotensin II (2 LM) for the
indicated times. The monolayer of cells was washed twice with
calcium-free phosphate-buffered saline containing 2.5 mrvi EGTA
and 2.5 mi EDTA. The cells were then pelleted and sonicated in
homogenization buffer (20 m Tris-Ci, pH 7.5, 0.5 mM EGTA, 0.5
mM EDTA, 1 mi DTT, 1 mM PMSF, 10 pg/mi aprotinin). After
centrifugation for 30 minutes at 100,000 x g, the supernatant,
containing the cytosolic fraction, was assayed for PKC activity (see
below). The membrane fraction was then treated with homogeni-
zation buffer containing, in addition, 1% Triton X-100 and
centrifuged for 30 minutes at 100,000 X g. This supernatant was
diluted to 0.2% Triton X-100 and assayed for PKC activity. For
analysis of PKC activity, membrane and cytosolic fractions were
assayed separately. Reaction mixtures were prepared consisting of
5x reaction buffer [10 mrvi ATP, 50 mivi MgCI2, 0.5 mM CaCl2,
0.01% Triton X-100, and 100 mrvi Tris(hydroxymethyl)-amino
methane, pH 7.4], 5x activator solution [1 mg/mi phosphatidyl-
L-serine, 0.02 mg/mi 1,2-dioctanoyl-sn-giycerol (DiC8)], and PKC
substrate (dye-labeled glycogen synthase peptide). The superna-
tants from the cytosolic and membrane fractions were added to
reaction mixtures. Negative controls were also prepared with the
above reaction mixture in which phosphatidyl-L-serine was omit-
ted. These were incubated at 30°C for 30 minutes. After incuba-
tion, 20 jtl of each sample was applied directly onto an ATP-
binding affinity membrane in order to stop the reaction.
Phosphopeptide binding buffer (0.1 M sodium acetate, 0.5 M
sodium chloride, and 0.02% sodium azide, pH 5.0) was added to
the membrane for three minutes. The membranes were centri-
fuged at 5000 rpm in a microcentrifuge twice for one minute each
time. Phosphopeptide eiution buffer (0.1 M ammonium bicarbon-
ate, 0.02% sodium azide, pH 8.0) was then added to the mem-
brane for three minutes and centrifuged twice at 5000 rpm.
Spectrophotometric readings were taken on both these cytosolic
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Fig. 1. Dose response of inhibition by TGF-pl. VSM cells were grown to
confluence on 24-well culture dishes and serum-deprived for two days with
serum-free quiescence media. TGF-f31 (T; at the concentrations indicated
in ng/ml) and/or bFGF (F; 15 ng/ml) was added to the cells. After an
additional 18 hours, all wells were pulsed for five hours with [3H]thymidine
and incorporation of [3Hthymidine was assessed as described in the
Methods section. Each data point represents the mean SEM of three
wells and is representative of one of three separate experiments.
and membrane fractions, and the absorbance from the non-
activated lysate was subtracted from the activated lysate to
determine cellular localization of PKC.
Results
TGF-f31 inhibits bFGF-induced mitogenesis
TGF-/31 has been shown to either inhibit or stimulate mitogen-
esis, depending on conditions such as cell type and concomitant
growth factor addition [reviewed in 1]. To determine the nature of
TGF-/3's inhibitory effect on proliferation of VSM cells, we
examined [3H]thymidine incorporation into these cells after ex-
posure to the mitogen bFGF in the presence of TGF-pl at various
concentrations. The cells were serum-starved for two days prior to
exposure to growth factors in order to induce the quiescent state.
Subsequently bFGF, TGF-pl, or both, were added simulta-
neously, and, after 18 hours, the cells were pulsed with [3Hjthy-
midine.
bFGF caused a ninefold increase in DNA synthesis as com-
pared to control cells (Fig. 1), consistent with our previous results
[18]. In the presence of TGF-/31 at concentrations ranging from
0.01 ng/ml to 1 ng/ml, DNA synthesis was decreased by a relatively
constant amount as compared to basal levels, with maximal
inhibition (79%) occurring at 1 ng/ml. This inhibition of DNA
synthesis in serum-deprived cells was likely due to incomplete
quiescence and/or to inhibition of autocrine and paracrine growth
factor pathways. When the two growth factors were added simul-
taneously, the level of [3Hjthymidine incorporation due to bFGF
was inhibited in a dose-dependent manner, from 49% of bFGF
levels at 0.01 ng/ml to 79% at I ng/ml. At concentrations of
TGF-f31 between 1 and 10 ng/ml, there was no further decrease in
bFGF-stimulated [3Hjthymidine incorporation (data not shown),
suggesting that the TGF-131 receptors were saturated at 1 ng/ml,
in agreement with results in hamster fibroblasts from another
laboratory [19]; we therefore used TGF-f31 at a concentration of
5 ng/ml in subsequent experiments.
Inhibition by PMA ofbFGF-induced mitogenesis is similar to that
of TGF-pl
Activation of PKC has been shown to mediate inhibitory as well
as stimulatory effects in a variety of cell types [20, 211. We [171 and
others [12, 13] have shown that the inhibitory effect of PMA on
thrombin-induced mitogenesis in neonatal rat VSM cells is max-
imal when the two compounds are added either simultaneously or
separated in time by up to four hours. This effect was demon-
strated to be due to activation of PKC, as it was reversed by the
PKC inhibitor, sphingosine [17]. To assess whether a similar effect
occurs with bFGF, we performed analogous experiments to
determine the effect of PMA on the mitogenic action of this
growth factor.
TGF-j3 inhibits DNA synthesis when added to cells at times
ranging from at least four hours before to four hours after bFGF
addition (data not shown), with the maximal inhibitory effect
occurring with addition four hours after, similar to the effect of
PMA on thrombin's inhibitory effect [121. When added four hours
after bFGF, TGF-f3 and PMA both inhibited bFGF-induced
mitogenesis in a quantitatively similar fashion: TGF-131 inhibited
mitogenesis by 71% (Fig. 2A), while PMA inhibited mitogenesis
by 84% (Fig. 2B). The decrement in [3Hthymidine incorporation
as compared to control after addition of TGF-f3 likely represents
incomplete quiescence of the cells or interference with autocrine
pathways as discussed above. However, the decrease in DNA
synthesis after PMA or TGF-f3 addition relative to bFGF stimu-
lation is quantitatively similar.
TGF-/31 stimulates PKC activity without increasing PKC quantity
Upon activation, PKC is translocated from the cytosolic to the
membrane fraction of the cell [20, 22, 23]. Since both PMA and
TGF-/31 cause inhibition of bFGF-stimulated DNA synthesis with
similar time courses, we next asked whether the time course of
PKC translocation was similar for these two compounds. Mem-
brane and cytosolic fractions were separated and each fraction
was assayed for DiC8-activatable kinase activity. To separate out
kinase activity that was not due to PKC, activity derived from
lysate which was not activated by phosphatidylserine was sub-
tracted from the same quantity of lysate which had been activated
by this lipid [241. Angiotensin II was used as a positive control,
since it is known to strongly activate PKC through endogenously
produced diacylglycerol [23].
When serum-starved VSM cells were exposed to PMA, there
was an increase in membrane-associated PKC activity starting
within 15 minutes of PMA addition and persisting for more than
60 minutes, and a corresponding decrease in cytosolic PKC
activity (Fig. 3A). This is consistent with many earlier studies on
the phorbol esters and demonstrates the reliability of the assay. In
other experiments, TGF-131 was added to the cells, resulting in
translocation of PKC activity also starting within 15 minutes (Fig.
3B). However, in the case of TGF-/31, the membrane-associated
activity begins to decline after 30 minutes, consistent with the fact
that this growth factor probably causes stimulation of PKC
through production of the unstable intermediate diacylglycerol,
whereas PMA is a stable molecule and causes more persistent
activation of PKC. Since angiotensin II is known to activate PKC
through the production of diacylglycerol [23], this vasoactive
peptide was also examined as a control. When VSM cells were
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Fig. 2. Effect of PMA and TGF-pI on bFGF-induced mitogenesis. VSM
cells were grown to confluence on 24-well culture dishes and serum-
deprived as in Figure 1. Two separate sets of experiments were performed.
To some wells, (A) bFGF (15 nglml) or TGF-pl (5 nglml) was added
alone, and in the other wells TGF-131 was added four hours after bFGF
addition (column F[+4]). In the other series of experiments, (B) bFGF(15
nglml) or PMA (100 nglml) was added alone, and in the other wells PMA
was added four hours after bFGF addition (column F[+41). After an
additional 18 hours, [3Hjthymidine incorporation was assessed as in
Figure 1. Each data point represents the mean SEM of three wells and
is representative of one of two separate experiments.
exposed to angiotensin II (Fig. 3C), PKC activated was translo-
cated with a time course similar to that seen with TGF-131,
suggesting that TGF-f3 is acting through production of endoge-
nous diacylglycerol.
To determine whether the increase in PKC activity upon
stimulation of cells with TGF-f31 was due to increased PKC
protein rather than to increased catalytic activity alone, we
examined levels of PKC-a and PKC-f311, the only two conven-
tional PKC isoenzymes detected in rat aortas [251. In similar
fashion to the PKC translocation experiments (Fig. 3), serum-
starved VSM cells were exposed to TGF-131 for various times
ranging from 15 minutes to one hour. The cells were lysed and
Western blots were performed with polyclonal antibodies raised
against peptides within the carboxy termini of PKC-a and PKC-
DII. In the case of PKC-cw, several bands appeared on the blot,
migrating at molecular weights ranging from 48 to 80 kD (Fig.
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Fig. 3. Time course of PKC translocation by PMA and TGF-131. VSM cells
were grown to confluence on 6 cm dishes and serum-deprived as in Figure
1. After stimulation with (A) PMA (100 ng/ml), (B) TGF-f31 (5 nglml), or
(C) angiotensin-Il (2 jiM) for the indicated times, the cells were lysed and
the lysatc was analyzed for cytosolic (circles) and membrane (squares)
PKC activity in the presence of DiC8 as described in the Methods section.
The absorbance displayed is the difference between lysatc stimulated with
DiC8 in the presence from that in the absence of phosphatidylserine, to
correct for non-specific kinase activity. The experiments shown are
representative of one of two separate experiments.
4A). To demonstrate that the 80 kD band corresponded to
PKC-a, a parallel experiment was performed with the same cell
lysate in which the filter was incubated with the antibody to
' yw,zaM
S
a
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Fig. 5. Western blot of PKC-1311 after exposure to TGF-131. VSM cells were
stimulated with TGF-131 (5 ng/mI) for the indicated time, lysed and equal
quantities of lysate were electrophoresed on a 7.5% SDS-polyacrylamide
gel and transferred to nitrocellulose as in Figure 4. The filter was probed
with rabbit polyclonal antibody to PKC-J311 and then with goat anti-rabbit
horseradish peroxidase coupled IgG. The subsequent blot was visualized
by enhanced chemiluminescence. The arrow marks PKC-f311; molecular
weight markers are shown at the left. The experiment shown is represen-
tative of one of three separate experiments.
Table 1. Densitometry of PKC protein bands
Time minutes
0 15 30 60
PKC-a 95.6 3.62 75.6 7.13 71.1 354a 88.4 4.79
PKC-3 82.7 7.26 69 8.17 86.3 6.39 68.1 13.7
The 80 kD bands on the PKC-a and PKC-13 Western blots shown in
Figs. 4 and 5 were analyzed by laser densitometry. Data reported
represents the mean of three repetitions of each experiment and is
in arbitrary densitometry units.
a Significant decrease (P < 0.05) compared to PKC-n at t = 0.
49.5 —
Fig. 4. Western blot of PKC-cx after exposure to TGF-pl. VSM cells were
grown to confluence on 6 cm dishes and serum-deprived as in Figure 1.
After stimulation with TGF-pl (5 ng/ml) for the indicated time, cells were
lysed and equal protein quantities of lysate were electrophoresed on a
7.5% SDS-polyacrylamide gel and transferred to nitrocellulose. The filter
was probed with (A) rabbit polyclonal antibody to PKC-a and then with
goat anti-rabbit horseradish peroxidase coupled IgG. (B) The same lysate
was electrophoresed in identical fashion, but was immunoblotted with
antibody to PKC-a in the presence of a tenfold excess of C-20 PKC-n
neutralizing peptide antigen. The subsequent blots were visualized by
enhanced chemiluminescence. The arrow marks PKC-a; molecular weight
markers are shown at the left. The experiments shown are representative
of one of three separate experiments.
PKC-a in the presence of a tenfold excess of C-20 PKC-a peptide
antigen as a neutralizing agent. In this case, only the 80 kD band
was absent (arrow, Fig. 4B), demonstrating that this band in fact
corresponds to PKC-a. Similar experiments were performed using
polyclonal antibody to PKC-pII (Fig. 5). Laser densitometry of
the 80 kD bands from three separate experiments showed no
significant increases in PKC protein compared to control at the
times corresponding to activation of the membrane fraction
(Table 1), suggesting that the change in PKC activity in response
to TGF-/31 is due to translocation and subsequent catalytic
activation of the enzyme and not to increased transcription or
translation of PKC protein.
PKC down-regulation attenuates TGF-131-mediated growth
To demonstrate that PKC plays an essential role in TGF-f3-
mediated growth inhibition, we examined the effect of this growth
factor on bFGF-induced mitogenesis after attenuation of PKC.
Pre-incubation of VSM cells with PMA for 24 hours causes total
loss of PKC activity in this cell type [12, 17] as well as in other
116.5—
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Fig. 6. Effect of TGF-131 on bFGF-induced mitogenesis after long-term
PMA incubation. VSM cells were grown to confluence on 24-well culture
dishes and serum-deprived as in Figure 1. To half of the wells, PMA (100
nglml) was added for 24 hours (), whereas to the other half no PMA was
added (U). Subsequently, bFGF (F; 15 ng/ml), TGF-/31 (T; 5 nglml), or
both (T+F) were added where indicated. Simultaneously, [3H]thymidine
(1 /LCi/well) was added to all wells. Incorporation of [3H]thymidine 24
hours later was assessed as described in the Methods section. Each data
point represents the mean SEM of four separate experiments, expressed
as percent of maximal bFGF stimulation. *Signiflcant decrease (P < 0.05),
calculated by the paired t test, relative to F+T with PMA pre-incubation.
systems [26]; we have previously shown that the DMSO carrier for
PMA has no effect on VSM cell mitogenesis [27]. In both the
presence or absence of 24-hour PMA pre-treatment, there was no
significant change in either the magnitude of bFGF-induced
mitogenesis or of TGF-1-induced inhibition of mitogenesis
relative to basal (Fig. 6). However, the inhibitory effect of TGF-131
on bFGF-stimulated mitogenesis was completely abolished after
24 hours PMA incubation, suggesting that such inhibition by
TGF-/3 requires PKC activity for its full effect.
Discussion
TGF-/3 has been shown to mediate pleiotropic effects on
mitogenesis in a variety of cell systems [reviewed in 1]. It
stimulates extracellular matrix production in some fibroblastic cell
lines, and it increases production of several proteoglycans in
mesangial cells [28], concomitant with growth inhibition [91• In
both cultured vascular smooth muscle and renal mesangial cells,
TGF-/3 has been reported to have a bimodal effect on mitogenesis,
depending on the confluency of the cells [3, 29]. In the case of
phorbol esters, we [17] and others [13, 30] have previously shown
that PMA, when incubated with certain growth factors and under
certain conditions, causes inhibition of thrombin-stimulated mi-
togenesis in vascular smooth muscle cells in a manner similar to
TGF-/3. Since both TGF-/3 and PMA possess similar mitogenic
properties, we suspected that they may be acting on parallel
signaling pathways. We now show that: (I) both PMA and TGF-pl
cause inhibition of bFGF-induced mitogenesis when added four
hours after bFGF, reminiscent of the inhibitory effect of PMA on
the G-protein coupled growth factor c-thrombin [13, 30], (ii) both
PMA and TGF-f31 cause translocation of cellular PKC with
similar time courses, and (iii) after down-regulation of PKC by
long-term incubation of the cells with PMA, the mitogenic
inhibitory effect of TGF-f31 is diminished. The most likely expla-
nation for these effects is that TGF-131 is causing stimulation of
PKC catalytic activity and that PKC, in turn, is phosphorylating
downstream effectors, in some as yet unclear manner, to bring
about growth inhibition. The observations by other investigators
that both TGF-p and PMA inhibit the cell cycle at the same point,
that is, TGF-f3 inhibits NRK and NIH-3T3 fibroblasts at the G1IS
transition [311 or in G1 [32, 33], and PMA obstructs transit
through the cell cycle "early" in the cycle [12] or at G1IS [151,
strengthen our conclusions.
TGF./3 has been shown to mediate the mesangial sclerosis
following experimental acute glomerulonephritis in animals [5,
34] and has been hypothesized to be involved in regeneration after
renal ischemic injury [35] and in the hypertrophic effect of
hyperglycemia in on proximal tubule [36] and mesangial [37] cells
in diabetic nephropathy. Furthermore, this peptide is involved in
the growth response of VSM cells to angiotensin II, an event
which may be important in the response of arterial VSM cells in
vivo to cell injury resulting in hypertension and atherosclerosis [61.
Because of the relevance of this growth factor to renal and
vascular diseases, much work in recent years has focused on the
mechanism of action of TGF-f3 after receptor binding. We now
show a surprising parallel between the mechanism of action of
TGF-13 and that of the potent tumor promoter PKC in cultured
VSM cells in addition to a dependence of TGF-J3's inhibitory
effect on PKC activation. We further show that the two com-
pounds cause stimulation of PKC in an analogous fashion due to
an increase in enzyme translocation and presumably catalytic
activity and not to alterations in PKC protein level.
Parallel activation of signaling pathways by an inhibitory growth
factor and a tumor promoter leads to speculation on the evolu-
tionary significance of the convergence of these pathways. The
teleological role of TGF-f3 may be to decrease transit through the
cell cycle in order to divert the cellular machinery into the
differentiation mode in order to synthesize matrix, etc. [9].
Similarly, PKC has been shown to have a dual role in cellular
regulation: both a positive forward action on growth regulation as
well as a negative feedback activity [20]. Indeed, the bimodal
effects of TGF-f3, being growth promoting under some conditions
and growth inhibitory in others, provides a striking parallel with
the phorbol ester family. PMA, under conditions of acute stimu-
lation, activates intracellular events associated with mitogenesis,
while under conditions of chronic exposure, there is down-
regulation of PKC and associated events, and an inhibitory
response of second messengers.
Others have demonstrated activation of PKC by TGF-p. Wrenn
et al [38] found an increase in the mass amounts of sn-1,2-
diacylglycerol in the membranes of neural crest-derived cultured
avian vascular smooth muscle cells which correlated with in-
creased translocation of PKC from the cytoplasm to the mem-
brane. Robertson et al [22] showed that TGF-13 stimulates both
phosphatidylinositol metabolism and translocation of PKC in
cultured neonatal rat astrocytes. However, our data are the first to
our knowledge to provide evidence linking the activation of PKC
with the growth inhibitory activity of both TGF-f3 and PMA.
While the inhibitory effects of TGF- have been known for
some time, the pathways utilized by these substances to constrain
growth continues to be the subject of much investigation. In light
of the results of this study, we speculate that TGF-/3 may be an
endogenous activator of the growth inhibitory pathway mediated
by PKC [12—15, 171. Since TGF-f3 is not only associated with
growth inhibition, but appears to be intimately involved in the
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switch to the differentiated phenotype and to hypertrophy of a
number of cell types [6, 9, 39], further investigation in this area
may lead to avenues of therapeutic interventions for renal as well
as other diseases.
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